## **Francis Giraud**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1244823/publications.pdf Version: 2024-02-01



FRANCIS CIRALID

#	Article	IF	CITATIONS
1	Synthesis, Protein Kinase Inhibitory Potencies, and in Vitro Antiproliferative Activities of Meridianin Derivatives. Journal of Medicinal Chemistry, 2011, 54, 4474-4489.	6.4	100
2	Synthesis and structure–activity relationships of 2-phenyl-1-[(pyridinyl- and) Tj ETQq0 0 0 rgBT /Overlock 10 Medicinal Chemistry Letters, 2009, 19, 301-304.	Tf 50 707 1 2.2	Td (piperidinylı 42
3	Efficient microwave-assisted synthesis of 1-(1H-indol-1-yl)-2-phenyl-3-(1H-1,2,4-triazol-1-yl)propan-2-ols as antifungal agents. Tetrahedron Letters, 2006, 47, 6479-6483.	1.4	40
4	Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co–crystal structure. European Journal of Medicinal Chemistry, 2016, 118, 170-177.	5.5	34
5	Design, synthesis, and evaluation of 1-(N-benzylamino)-2-phenyl-3-(1H-1,2,4-triazol-1-yl)propan-2-ols as antifungal agents. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1820-1824.	2.2	32
6	New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis. European Journal of Medicinal Chemistry, 2019, 166, 304-317.	5.5	32
7	Synthesis and biological activities of 4-substituted pyrrolo[2,3-a]carbazole Pim kinase inhibitors. European Journal of Medicinal Chemistry, 2012, 56, 225-236.	5.5	28
8	An efficient route from coumarins to highly functionalized N-phenyl-2-quinolinones via Buchwald–Hartwig amination. Tetrahedron Letters, 2003, 44, 4207-4211.	1.4	24
9	Design of new antifungal agents: synthesis and evaluation of 1-[(1H-indol-5-ylmethyl)amino]-2-phenyl-3-(1H-1,2,4-triazol-1-yl)propan-2-ols. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5833-5836.	2.2	22
10	Design, Synthesis, and inâ€vitro Antifungal Activity of 1â€{(4â€Substitutedâ€benzyl)methylamino]â€2â€{2,4â€difluorophenyl)â€3â€{1 <i>H</i> â€1,2,4â€triazolâ€1 ChemMedChem, 2011, 6, 816-825.	â€yl}p <b>z</b> opa	nâ€ <b>2</b> ⁄â€ols.
11	Synthesis and biological activity of pyrazole analogues of the staurosporine aglycon K252c. Bioorganic and Medicinal Chemistry, 2016, 24, 3116-3124.	3.0	17
12	Synthesis and preliminary in vitro kinase inhibition evaluation of new diversely substituted pyrido[3,4-g]quinazoline derivatives. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4327-4329.	2.2	17
13	Design, synthesis and evaluation of 3-(imidazol- 1-ylmethyl)indoles as antileishmanial agents. Part II. Journal of Enzyme Inhibition and Medicinal Chemistry, 2009, 24, 1067-1075.	5.2	14
14	Synthesis of pyrazolo[4,3-a]phenanthridines, a new scaffold for Pim kinase inhibition. Bioorganic and Medicinal Chemistry, 2014, 22, 4704-4710.	3.0	14
15	New N-1,N-10-bridged pyrrolo[2,3-a]carbazole-3-carbaldehydes: Synthesis and biological activities. Bioorganic Chemistry, 2014, 57, 108-115.	4.1	14
16	A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia. Molecular Cancer Therapeutics, 2019, 18, 567-578.	4.1	13
17	Kinase inhibitions in pyrido[4,3-h] and [3,4-g]quinazolines: Synthesis, SAR and molecular modeling studies. Bioorganic and Medicinal Chemistry, 2019, 27, 2083-2089.	3.0	11
18	Recent Advances in Pain Management: Relevant Protein Kinases and Their Inhibitors. Molecules, 2021, 26, 2696.	3.8	11

FRANCIS GIRAUD

#	Article	IF	CITATIONS
19	Synthesis and Applications of Dihydropyrrolocarbazoles. European Journal of Organic Chemistry, 2019, 2019, 5025-5042.	2.4	10
20	Synthesis and biological evaluation of Haspin inhibitors: Kinase inhibitory potency and cellular activity. European Journal of Medicinal Chemistry, 2022, 236, 114369.	5.5	7
21	Synthesis and activities of new indolopyrrolobenzodiazepine derivatives toward acute myeloid leukemia cells. Bioorganic and Medicinal Chemistry, 2015, 23, 7313-7323.	3.0	6
22	Synthesis and antiproliferative evaluation of glucosylated pyrazole analogs of K252c. Tetrahedron, 2018, 74, 892-901.	1.9	6
23	Synthesis of N-aryl-3-(indol-3-yl)propanamides and their immunosuppressive activities. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5203-5206.	2.2	5
24	Pyridin-2(1H)one derivatives: A possible new class of therapeutics for mechanical allodynia. European Journal of Medicinal Chemistry, 2020, 187, 111917.	5.5	5
25	A 3D-QSAR CoMSIA study on 3-azolylmethylindoles as anti-leishmanial agents. SAR and QSAR in Environmental Research, 2006, 17, 299-309.	2.2	3
26	Synthesis and biological activities of new pyrrolocarbazole-imidazobenzimidazole conjugates. Tetrahedron Letters, 2020, 61, 152096.	1.4	3
27	Heteroaromatic Pim Kinase Inhibitors Containing a Pyrazole Moiety. Recent Patents on Anti-Cancer Drug Discovery, 2016, 11, 309-321.	1.6	3
28	Synthesis and kinase inhibitory potencies of new pyrido[3,4-g]quinazolines substituted at the 8-position. Arkivoc, 2021, 2020, 105-116.	0.5	1
29	An Efficient Route from Coumarins to Highly Functionalized N-Phenyl-2-quinolinones via Buchwald—Hartwig Amination ChemInform, 2003, 34, no.	0.0	0
30	Improved potency of pyridin-2(1H)one derivatives for the treatment of mechanical allodynia. European Journal of Medicinal Chemistry, 2021, 225, 113748.	5.5	0